Wave Life Sciences Files 13D/A on March 30 Wave Life Sciences filed a Form 13D/A on 30 Mar 2026; Schedule 13D disclosure is triggered at >5% ownership and must be filed within 10 days (SEC 17 CFR 240.13d-1).

Wave Life Sciences Files 13D/A on March 30: Wave Life Sciences filed a Form 13D/A on 30 Mar 2026; Schedule 13D disclosure is triggered at >5% ownership and must be filed within 10 days (SEC 17 CFR 240.13d-1). 👈 Read full analysis #WaveLifeSciences #Form13DA #SEC #StockMarket #Investment

Wave's stock wavers on obesity drug data Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.

#WaveLifeSciences has said new #clinicaltrialresults with its non-incretin therapy for #weightloss are positive – but #investors don't seem to agree.

pharmaphorum.com/news/waves-s...

Wave Life Sciences Stock Reiterated Outperform by Leerink Leerink reiterated Outperform on Wave Life (NASDAQ: WVE) on Mar 26, 2026; note follows recent clinical disclosures and shifts short-term liquidity and event risk.

Wave Life Sciences Stock Reiterated Outperform by Leerink: Leerink reiterated Outperform on Wave Life (NASDAQ: WVE) on Mar 26, 2026; note follows recent clinical disclosures and shifts short-term liquidity and event… 👈 Read full analysis #WaveLifeSciences #Leerink #StockMarket #Investing #BioTech

WVE Stock Drops 30% on INLIGHT Obesity Trial Data WVE stock plunged 30% after Wave Life Sciences released Phase 1 INLIGHT trial results. See what the data showed and why investors sold off shares.

WVE Stock Drops 30% on INLIGHT Obesity Trial Data
WVE stock plunged 30% after Wave Life Sciences released Phase 1 INLIGHT trial results. See what the data showed and why investors sold off sh...

#WVE #WaveLifeSciences #INLIGHT #ObesityTrial #BiotechStocks
https://scrollworthy.org/trending/wve-stock

Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

#Pfizer #obesity #weightloss #FosunPharma #YaoPharma #GLP1agonist #oralGIPanalogue #Metsera #EliLilly #NovoNordisk #Wegovy #ZealandPharma #metabolicdiseases #Roche #BoehringerIngelheim #GLP1glucagonagonist #StructureTherapeutics #AscletisPharma #WaveLifeSciences #Gubra
zurl.co/AwsrK

Nice 80% #RNAediting efficiency in patient-derived cells at therapeutically relevant #oligonucleotide concentrations. If #ProQR can take advantage of #FDA platform pathway, #Rett opportunity very exciting.

#WaveLifeSciences, once saying they are out of correcting mutations, are also on it.

I mentioned Prime and Beam because they can 'fix' genes with base and prime editing. Approach also applies to ADAR #RNAediting when targeted at individual mutations, e.g. in #RettSyndrome. #ProQR #WaveLifeSciences

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track f...

#WaveLifeSciences programs likely listed in order of belief mgmt has in their value (to company):
1) InhibinE RNAi (dosing ongoing) for obesity
2) AATD #RNAediting multi-dose 200mg and single-dose 400mg
3) DMD skippers
4) Huntington'sDisease allele-specific ASOs
finance.yahoo.com/news/wave-li...

AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline — Airna Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new

$155M Series B investment into preclin #ADAR Therapeutics Co #Airna, highlighting strong interest in modality despite challenging biotech environment.

$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro

Wishful thinking as this is an oral drug.

But yes, if #PTCTherapeutics can confirm last year's data in Q2, then it would be a positive for #WaveLifeSciences. #UniQure #Huntington'sDisease

Wave Life Sciences shares surge on positive DMD trial results Investing.com -- Shares of Wave Life Sciences Ltd . (NASDAQ:WVE) rose 14% today, following the company’s announcement of positive results from its FORWARD-53 clinical trial in Duchenne muscular dystrophy (DMD), which showed significant functional benefits and reversal of muscle damage after 48 weeks of dosing with its investigational drug WVE-N531. The Cambridge-based biotech firm revealed that the Phase 2 trial met all its goals, demonstrating sustained and leading exon skipping, muscle concentrations, and dystrophin restoration. The trial’s results also indicated a 61-day tissue half-life for the drug, which supports the potential for monthly dosing. The drug was reported to be safe and well-tolerated, with no Serious Adverse Events. Notably, the trial showed a statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise (TTR) compared to natural history, and additional functional benefits were observed in other outcome measures, including the North Star Ambulatory Assessment (NSAA). Moreover, the trial demonstrated a significant reduction in muscle fibrosis and decreases in creatine kinase and circulating inflammatory biomarkers. Wave Life Sciences also intends to file a New Drug Application (NDA) for accelerated approval of WVE-N531 in 2026, following recent feedback from the FDA. The company plans to file clinical trial applications (CTAs) for multiple DMD candidates for other exons in 2026, with preclinical data supporting a best-in-class exon skipping franchise. Jones Research analyst Catherine Novack commented on the results, stating, "Muscle-content adjusted dystrophin at 48 weeks was 6.4% vs 9.0% at 24 weeks (avg: 7.8%), with 88% of patients averaging above 5%. This falls below the 10% threshold that is expected to confer clinical benefit, but still significantly greater than other exon 53 skippers at 48 weeks. Time to rise from the floor improved by 3.8 seconds vs natural history. This is impressive, though we would like to see placebo-controlled functional data given the heterogeneity of the disease." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #WaveLifeSciences #DMD #ClinicalTrials #PharmaNews #StockMarket

Wave reportó una expresión de distrofina promedio de 5.5% (no ajustado por contenido muscular) que fue altamente consistente entre los participantes.👥

🔗Lee el artículo completo en el link: lnkd.in/eh9aTJ2W

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #WaveLifeSciences